作者
Styliani Karanika, Theodoros Karantanos, Shinji Kurosaka, Jianxiang Wang, Takahiro Hirayama, Guang Yang, Sanghee Park, Alexei A Golstov, Ryuta Tanimoto, Likun Li, Timothy C Thompson
发表日期
2015/12
期刊
Molecular cancer
卷号
14
页码范围
1-13
出版商
BioMed Central
简介
Background
Docetaxel is the first chemotherapy agent approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminished its efficacy. JNK-mediated apoptosis is one of the mechanisms of docetaxel activity whereas ERK1/2-c-Myc-CXCR4 signaling is implicated in the development of resistance and induction of migration. The aim of this study was to evaluate the hypothesis that the combination treatment with docetaxel and GLIPR1-ΔTM will synergistically induce greater cell death and inhibit the emergence of resistance and development of metastatic potential in prostate cancer (PCa) cells.
Methods
The synergistic effects of the docetaxel and GLIPR1-ΔTM were evaluated with DNA fragmentation, DAPI staining and MTS using …
学术搜索中的文章
S Karanika, T Karantanos, S Kurosaka, J Wang… - Molecular cancer, 2015